Isooctanamide, N,N-dimethyl-

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Isooctanamide, N,N-dimethyl-
• 英文别名: N,N,6-trimethylheptanamide
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: ZXIGDIQXDFSEEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY<br/>[FR] AGONISTES DE CNP À LIBÉRATION CONTRÔLÉE AVEC FAIBLE ACTIVITÉ NPR-B INITIALE
  申请人：ASCENDIS PHARMA GROWTH DISORDERS AS

  公开号：WO2017118703A1

  公开（公告）日：2017-07-13

  The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.

  本发明涉及一种受控释放的CNP激动剂，其中在生理条件下，CNP激动剂以至少6小时的释放半衰期释放，并且该受控释放的CNP激动剂的EC50至少比相应的游离CNP激动剂的EC50高20倍，并且释放的CNP激动剂的EC50至多比相应的游离CNP激动剂的EC50高3倍；以及包含所述受控释放的CNP激动剂的药物组合物；其用途；以及治疗方法。
• [EN] CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS<br/>[FR] AGONISTES DE CNP À LIBÉRATION CONTRÔLÉE PRÉSENTANT DES EFFETS SECONDAIRES RÉDUITS
  申请人：ASCENDIS PHARMA GROWTH DISORDERS AS

  公开号：WO2017118707A1

  公开（公告）日：2017-07-13

  The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

  本发明涉及一种包含控释CNP激动剂的药物组合物，该药物组合物减少了与CNP激动剂相关的副作用，以及使用这种控释CNP激动剂和治疗方法。
• NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF
  申请人：S&T Global Inc.

  公开号：EP3831841A1

  公开（公告）日：2021-06-09

  A compound of the Formula (I) is disclosed: or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

  公开了一种式 (I) 的化合物： 或其药学上可接受的盐，其中符号如说明书中所定义。还描述了包含该化合物的药物组合物，以及使用该化合物治疗或预防病毒感染、炎症、干眼症、中枢神经失调、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺病、肝病、肾病和脱发的方法。
• [EN] CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING<br/>[FR] AGONISTES DE CNP À LIBÉRATION CONTRÔLÉE PRÉSENTANT UNE FAIBLE LIAISON À NPR-C
  申请人：ASCENDIS PHARMA GROWTH DISORDERS AS

  公开号：WO2017118704A1

  公开（公告）日：2017-07-13

  The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.